| answer text |
<p>Licensed cannabis-based medicines are routinely available on the National Health
Service. However, clinical guidelines from the National Institute for Health and Care
Excellence demonstrate a clear need for more evidence to support routine prescribing
and funding decisions for unlicensed cannabis-based medicines.</p><p>Funding of unlicensed
products is subject to local National Health Service decisions on a case-by-case basis.
These decisions follow clearly developed procedures that ensure equitable distribution
of funding, prioritising those medicines that have proved their safety, quality, and
clinical and cost effectiveness.</p><p>We continue to call on manufacturers to conduct
research to prove if their products are safe and effective and we are working with
regulatory, research and NHS partners to establish clinical trials to test the safety
and efficacy of these products.</p>
|
 |
